Compare Stocks

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
EOLS Evolus	$11.89 -1.7%	$13.72	$7.07 ▼ $15.43	$688.95M	1.45	635,747 shs	965,411 shs
OBSV ObsEva	$0.00	$0.03	$0.08 ▼ $2.14	$31K	0.68	8.94 million shs	3,001 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-27.27%
EOLS Evolus	-1.65%	-10.60%	-14.46%	+14.00%	+41.72%
OBSV ObsEva	-92.00%	-92.00%	-97.33%	-98.86%	-99.57%

REVEALED: Elon Musk’s Secret A.I. Facility? (Ad)

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	4.1966 of 5 stars	3.5	3.0	0.0	3.5	3.2	2.5	0.6
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
EOLS Evolus	3.00	Buy	$20.60	73.25% Upside
OBSV ObsEva	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OBSV, ADMS, CYAD, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/1/2024	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
1/29/2024	EOLS Evolus	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$10.00 ➝ $16.00
1/17/2024	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
EOLS Evolus	$202.09M	3.41	N/A	N/A	($0.36) per share	-33.03
OBSV ObsEva	$20.11M	0.00	N/A	N/A	$0.41 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	-$61.69M	-$1.09	N/A	N/A	N/A	-30.52%	N/A	-32.19%	5/14/2024 (Estimated)
OBSV ObsEva	-$58.38M	-$0.92	N/A	∞	N/A	N/A	-416.36%	-92.01%	N/A

Latest OBSV, ADMS, CYAD, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	EOLS Evolus	-$0.15	-$0.20	-$0.05	-$0.19	$61.14 million	$61.00 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
CYAD Celyad Oncology	N/A	N/A	N/A
EOLS Evolus	N/A	2.33	2.10
OBSV ObsEva	N/A	0.61	0.61

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
CYAD Celyad Oncology	N/A
EOLS Evolus	90.69%
OBSV ObsEva	17.52%

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
CYAD Celyad Oncology	0.94%
EOLS Evolus	5.40%
OBSV ObsEva	14.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
EOLS Evolus	273	57.94 million	54.82 million	Optionable
OBSV ObsEva	48	77.97 million	66.74 million	Not Optionable

OBSV, ADMS, CYAD, and EOLS Headlines

Source	Headline
	ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com americanbankingnews.com - April 12 at 2:16 AM
	ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin globenewswire.com - April 3 at 1:00 AM
	ObsEva Announces Update on Board of Directors globenewswire.com - March 19 at 2:00 AM
	ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 globenewswire.com - February 28 at 1:00 AM
	ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates benzinga.com - February 26 at 12:34 AM
	ObsEva SA OBSN morningstar.com - November 11 at 10:37 PM
	ObsEva SA OBSEF morningstar.com - November 11 at 7:36 AM
	ObsEva (NASDAQ: OBSV) fool.com - June 18 at 11:34 PM
	Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver news.google.com - May 10 at 1:37 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance news.google.com - May 2 at 1:32 PM
	ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq news.google.com - May 2 at 8:31 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire news.google.com - May 2 at 1:20 AM
	Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz news.google.com - April 28 at 11:20 PM
	ObsEva Annual Report 2022 - Marketscreener.com news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Yahoo Finance news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Benzinga news.google.com - April 28 at 1:20 PM
	ObsEva Annual Report 2022 - EIN News news.google.com - April 28 at 1:20 PM
	Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire news.google.com - April 28 at 8:19 AM
	Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal news.google.com - April 26 at 6:27 PM
	Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR news.google.com - April 23 at 8:45 PM
	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com news.google.com - April 21 at 3:44 PM
	ObsEva Announces Change of Central Securities Depositary - Yahoo Finance news.google.com - April 20 at 11:41 PM
	ObsEva Announces Change of Central Securities Depositary - GlobeNewswire news.google.com - April 20 at 1:10 AM
	Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive news.google.com - April 13 at 6:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Evolus

NASDAQ:EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

ObsEva

NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial